Idera is currently a very high‑risk, distressed name and is not suitable for a typical 2‑month positional trade.

Key points you should know:

1. What “Idera” is today

- “Idera Pharmaceuticals, Inc.” (old ticker: IDRA, Nasdaq) acquired Aceragen in 2022. (nasdaq.com)

- On 17 Jan 2023 it changed its name to Aceragen, Inc. and its ticker to ACGN, along with a 1‑for‑17 reverse stock split. (nasdaq.com)

2. Delisting and distress

- On 4 Aug 2023, Aceragen announced that it would voluntarily delist from Nasdaq, file Form 25, and transfer/substantially assign its assets for the benefit of creditors (a classic insolvency/restructuring step). (nasdaq.com)

- A later notice confirmed that the last trading day on Nasdaq was 21 Aug 2023, and it would be delisted before the market opened on 22 Aug 2023. (theworldnewswire.com)

- My price feed still shows a last Nasdaq‑era price around USD 0.38 on 22 Aug (aligned with the delisting date), but that is historical, not current live data. (advfn.com)

3. What this means for a 2‑month view

- Business risk: The company explicitly moved toward assigning assets to creditors. Equity in such situations is typically a near‑zero recovery, highly speculative instrument. Common shareholders usually come last in the priority waterfall. (nasdaq.com)

- Listing / liquidity risk: It is no longer on Nasdaq. If it trades at all, it is likely on an OTC/grey market with:

- very low liquidity,

- wide bid‑ask spreads, and

- difficulty entering/exiting within tight price limits.

- Short‑term “2‑month” trading risk: Price action, if any, will be driven almost entirely by restructuring/legal news and occasional speculative flows—not by normal fundamentals. Moves can be extreme (multi‑bagger spikes or near‑total loss), and risk of permanent capital loss is very high.

4. Practical angle for an Indian investor (information only, not advice)

- Access from India to such a delisted/OTC U.S. name will in practice be limited to a few global brokers; many LRS‑enabled platforms will not support new purchases in a security that has been delisted from a major exchange.

- For a 2‑month trading horizon, investors usually prefer:

- listed, liquid stocks or ETFs,

- with transparent news flow and clear catalysts.

- Example (for illustration only): A typical short‑term trader building a 2‑month strategy would usually screen for average daily turnover, volatility, and event calendar (results, FDA decisions, etc.). A delisted micro‑cap under creditor assignment usually fails these liquidity and risk filters.

5. If you already hold Idera/Aceragen

- You are effectively in a special‑situation / distress bet.

- Typical risk‑management steps (examples, not advice):

- Be mentally prepared for a total loss scenario.

- Track official company filings (SEC/press releases) to understand whether there is any realistic equity recovery path.

- Decide in advance the maximum additional capital (if any) you are willing to risk, and avoid averaging down just because the price looks “cheap”.

You can read the official delisting announcement on Nasdaq’s site here (external link):

- Aceragen Inc. delisting press release: Nasdaq – “Aceragen, Inc. to Delist from The Nasdaq Stock Market”.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com